I agree. But we need to look back to where it all started to...

I agree. But we need to look back to where it all started to understand why it is what is was (so to speak).

CHM snapped up some high flyers from big pharma to chase that elusive CarT against solid tumour. Something not thought possible. These guys were at the top of their game and didnt come cheap. And cheap isnt the word that describes CarT treatment or development. The ozzie dollar was up, so costs didnt seem too bad for the savings they would bring through trial design etc.

Then things slowed down. Seems getting doctors trained up to administer the drug wasnt as easy as planned. I am wondering if this is where the problems with GOH started? Getting patients screened and dosed was taking longer than expected. More drain on financial pathway. A couple of CRs later and here we are.

As stated the threat is money in the bank. The pipeline is awesome, but that means nothing if the money runs dry.

What is needed is a cornerstone investor. And that is what our Bec is out to find. Until that happens nothing much will change. But for Bec to be able to do that job we need that pipeline to keep chugging along. And that needs cash. Sound s like a circular argument doesnt it?

The EV has no value. Although that is not nice, it does mean that even with the future dilution that will be needed, there is still room for lots of upside movement if they sort it out.

Very high risk. But dont you just love the challenge!